Recruiting
Age-related macular degeneration
RecruitingStudy on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease
Registered drugNo placebo
Study on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease
Registered drugNo placebo
- Disease:Age-related macular degeneration
- Substances:AfliberceptBrolucizumab+1
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Aflibercept
